The nursing attempt to organize the home environment for the experimental group will take 4 months. During this period, two home visits and two telephone calls will be made. During the first home visit, training will be organized to regulate the home environment. Temperature and humidity changes of the houses will be monitored during the operation with the heat-moisture meter device. During the first home visit, a temperature-humidity meter device, symptom log and temperature-humidity log tracking chart will be provided. Children in this group will be given an anti-allergic duvet cover. After 4 months, mothers' home environment arrangements, children's allergic rhinitis symptoms and quality of life changes will be examined.

The nursing initiative to regulate the home environment for the control group will take 4 months. During this time, two home visits will be made. During the first home visit, temperature-humidity meter device, symptom log and temperature-humidity log monitoring chart will be provided. After 4 months, mothers' home environment arrangements, children's allergic rhinitis symptoms and quality of life changes will be examined.

Allergic Rhinitis

training to organize a home environment. Examination of humidity and temperature changes in the home with a heat-moisture meter.
giving antiallergic duvet cover set.
heat-humidity measurement diary symptom diary

nursing intervention

Examination of humidity and temperature changes in the home with a heat-moisture meter.
heat-humidity measurement diary symptom diary

standard of care

Effect of Home Environment Regulation on Symptom Control and Quality of Life in Children With Allergic Rhinitis

The Effect of Nursing Initiative for Home Environment Regulation on Symptom Control and Quality of Life in Children With Allergic Rhinitis: A Randomized Controlled Study

Average quality of life score of children will be taken by using the Quality of Life Survey for 6-12 Years Old Children with Allergy in their Nose and Eyes. The scale includes scoring between 0-7. High average score indicates low quality of life.

The average score will be taken using the home environment evaluation form.this form was created by researchers.

weekly average with symptom monitoring form. The form created by the researchers aims to identify the symptoms of allergic rhinitis.forms are scored between 0-10.

muradiye aldem budak

research assistant

Necmettin Erbakan University

pretest-posttest, parallel group, randomized controlled study

Collection of blood and data from patients that receive allergen-immunotherapy (AIT) with Allergovit, an aluminium-containing AIT preparations.

Collection of blood and data from Patients that receive AIT with Polvac, an MCT-containing AIT preparation.

Collection of blood and data from patients that receive AIT with Pollinex Quattro, an MCT-MPLA containing AIT preparation.

Venous blood will be collected for the determination of lab parameters. Whole blood analysis will be performed on blood collected on ethylenediaminetetraacetic acid (EDTA), while inflammatory proteins and antibodies are analysed from blood serum and blood plasma.

Grass/tree-allergen extract with aluminium adjuvant for treatment of allergic rhinitis

Allergovit

Grass/tree-allergen extract with MCT adjuvant for treatment of allergic rhinitis

Polvac

Grass/tree-allergen extract with MCT-MPLA adjuvant for treatment of allergic rhinitis

Pollinex Quattro

Univeristy Hospital Zurich

Comparison of Innate Immune Responses Induced by Allergy Immunotherapy (AIT) With Different Adjuvants

The primary objective is to measure a change in inflammatory responses in blood from patients receiving AIT with Alum, MCT, or MCT-MPLA as adjuvants. 80-150 inflammatory proteins will be tested using an antibody array. The primary objective of this pilot study is not necessarily to identify single proteins, but to identify patterns of inflammatory proteins that changes over the course of the study and which may be characteristics for the different adjuvants utilized. The results will therefore be described as heat maps with the different proteins presented in fold increase (green colour) or fold decrease (red color) as compared to baseline values.

The acute-phase enzyme aspartate transaminase (ASAT) in blood from patients receiving AIT with Alum, MCT, or MCT-MPLA as adjuvants is analysed by a standard hospital laboratory method. The objective is to identify changes in ASAT (in U/l) compared to baseline values and which may be characteristics for the different adjuvants.

The acute-phase enzyme alanine aminotransferase (ALAT) in blood from patients receiving AIT with Alum, MCT, or MCT-MPLA as adjuvants is analysed by a standard hospital laboratory method. The objective is to identify changes in ALAT (in U/l) compared to baseline values and which may be characteristics for the different adjuvants.

The acute-phase protein gamma-glutamyltransferase (GGT) in blood from patients receiving AIT with Alum, MCT, or MCT-MPLA as adjuvants is analysed by a standard hospital laboratory method. The objective is to identify changes in GGT (in U/l) compared to baseline values and which may be characteristics for the different adjuvants.

The acute-phase protein C reactive protein (CRP) in blood from patients receiving AIT with Alum, MCT, or MCT-MPLA as adjuvants is analysed by standard hospital laboratory methods. The objective is to identify changes in CRP (in mg/l) compared to baseline values and which may be characteristics for the different adjuvants.

The acute-phase cytokine interleukin-6 (IL-6) in blood from patients receiving AIT with Alum, MCT, or MCT-MPLA as adjuvants is analysed by a standard hospital laboratory method. The objective is to identify changes in IL-6 (in ng/l) compared to baseline values and which may be characteristics for the different adjuvants.

The acute-phase mast cell protein tryptase in blood from patients receiving AIT with Alum, MCT, or MCT-MPLA as adjuvants is analysed by a standard hospital laboratory method. The objective is to identify changes in tryptase (in µg/l) compared to baseline values and which may be characteristics for the different adjuvants.

Allergen-specific IgM (in µg/l) antibody responses will be assessed in sera from patients receiving AIT with Alum, MCT, or MCT-MPLA as adjuvants. IgM is measured by an in-house sandwich ELISA method.

Allergen-specific total IgG (in mg/l) antibody responses will be assessed in sera from patients receiving AIT with Alum, MCT, or MCT-MPLA as adjuvants. IgG is measured by a standard hospital laboratory ELISA method.

Allergen-specific IgG4 (in µg/l) antibody responses will be assessed in sera from patients receiving AIT with Alum, MCT, or MCT-MPLA as adjuvants. IgG4 is measured by a standard hospital laboratory ELISA method.

Allergen-specific IgE (in kU/l) antibody responses will be assessed in sera from patients receiving AIT with Alum, MCT, or MCT-MPLA as adjuvants. IgE is measured by a standard hospital laboratory ImmunopCap method.

Pal Johansen

Professor

University of Zurich

Zentrums für Rhinologie und Allergologie Wiesbaden

Patients who decided to use only anti-allergic drugs during the grass pollen season

Revaccination With Pollinex® Quattro

Non-interventional Study A Multicentre Observational Study for Revaccination With Pollinex® Quattro in Patients With a Recurrent Grass Pollen Allergy

The CSMS consists of the six individual rhinoconjunctivitis scores for sneezing, rhinorrhoea, nasal pruritus, nasal congestion, ocular pruritus and watery eyes, the asthma scores for cough, breathlessness, wheeze and tightness in the chest as well as the score for the use of concomitant medication (oral antihistamines, nasal corticosteroids, oral corticosteroids, asthma inhalation spray). The symptoms and the use of drugs were documented in a diary: The symptom score was:
0=none, 1=mild, 2=moderate, 3=severe. Evaluation will be done for the peak of the grass pollen season, defined by those 30 consecutive days per center with the highest local grass pollen counts (according to Deutscher Wetterdienst Medizin-Meteorologie, http://www.dwd.de) measured in the nearest pollen count station in that region.

Prof. Dr. Ralph Mösges

University Hospital of Cologne

NS2 Ophthalmic Drops Vehicle (0.0%) control

Allergic Conjunctivitis

Seasonal Allergies

NS2 Ophthalmic Drops (0.5%)

NS2 Ophthalmic Drops Vehicle (0.0%)

Inflamax Research Inc.

A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis

A Randomized, Parallel, Single-Center, Double-Masked, Vehicle-Controlled Phase II Study to Evaluate the Activity of NS2 Ophthalmic Solution in Subjects With Allergic Conjunctivitis Using the Conjunctival Allergen Provocation Test (CAPT)

Mean change from baseline in ocular itching. Scores are entered as 0 (none), 1 (trace), 2 (mild), 3 (moderate), 4 (severe). Ocular itching will be collected through 180 minutes following allergen challenge at Visits 3, 3b, 4, 5, 6, and 7.

Mean change from baseline in conjunctival redness. Scores are entered as 0 (none), 1 (trace), 2 (mild), 3 (moderate), 4 (extremely severe). Scores are entered as 0 (none), 1 (mild), 2 (moderate), 3 (severe), 4 (extremely severe). Conjunctival redness will be collected through180 minutes following allergen challenge at Visits 3, 3b, 4, 5, 6, and 7.

Mean change from baseline in lid swelling. Scores are entered as 0 (none), 1 (trace), 2 (mild), 3 (moderate), 4 (extremely severe). Scores are entered as 0 (none), 1 (mild), 2 (moderate), 3 (severe), 4 (extremely severe). Lid swelling will be collected through180 minutes following allergen challenge at Visits 3, 3b, 4, 5, 6, and 7.

Mean change from baseline in ocular tearing scores. Scores are entered as 0 (none), 1 (mild), 2 (moderate), 3 (severe). Ocular tearing will be collected through 180 minutes following allergen challenge at Visits 3, 3b, 4, 5, 6, and 7.

Evaluate for presence of disease compared to baseline and descriptive statistics will be reported for the number of eyes with a change from baseline . A slit lamp exam evaluates the conjunctiva, cornea and anterior chamber of the eye with the aid of a slit lamp.

Evaluate presence of inflammation, disease and risk of glaucoma or retinal detachment and visual loss from baseline. Descriptive statistics will be reported for changes to the vitreous, retina, macula, blood vessels and the optic nerve.

IOP will be measured and recorded in mmHg and the change from baseline will be evaluated.

Treatment emergent adverse events will be summarized for all causality AEs and treatment related AEs. Treatment emergent AEs are those that first occured or worsened after the first dose of study medication.

Change from baseline in visual acuity and descriptive statistics will be reported.

Mean change from baseline in cytokine expression.

Aldeyra Therapeutics, Inc.

Pollen allergy and control will have the same intervention, ie. Skin prick test and collect serum samples.Then measure the specificIgE, immunoblot, and ELISA inhibition

Allergy to Grass Pollen

Allergic Rhinitis Due to Weed Pollens

serum specific IgE binds to grass extract by immunoblot

xanthorrhoea glauca/hypersensitivity

Effect of Home Environment Regulation on Symptom Control and Quality of Life in Children With Allergic Rhinitis

Comparison of Innate Immune Responses Induced by Allergy Immunotherapy (AIT) With Different Adjuvants

Revaccination With Pollinex® Quattro

A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis

Grass Sensitisation and Allergic Rhinitis in Thai Patients

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus